Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany -

3 hours ago

Study examines costs of stroke/systemic embolism and major bleeding in non-valvular atrial fibrillation patients switching from apixaban to rivaroxaban.
Both apixaban and rivaroxaban are direct oral anticoagulants but differ in risk profiles and side effects.
Model predicts increased clinical events and costs when switching to rivaroxaban compared to staying on apixaban.
In the USA, switching could increase costs by $17 million annually ($366.97 per treated person).
In Germany, switching could increase costs by €153 million annually (€150.21 per treated person).
Continuing apixaban is associated with better outcomes and lower event-related costs than switching to rivaroxaban.

Hasty Briefsbeta